New Drugs of 2013, Part 2

Michael A. Mancano, PharmD
Published Online: Monday, February 17, 2014

New Drugs of 2013, Part 2

Michael A. Mancano, PharmD
Clinical Professor of Pharmacy Practice
Chair, Department of Pharmacy Practice
Temple University
School of Pharmacy
Clinical Consultant
Pennsylvania Hospital, Department of Pharmacy
Philadelphia, Pennsylvania
The following contributors have no relevant financial relationships with commercial interests to disclose.
Michael A. Mancano, PharmD
Pharmacy Times Office of Continuing Professional Education
Planning Staff—David Heckard; Maryjo Dixon, RPh; and Steve Lin, PharmD, RPh
Pharmacy Times
Editorial Staff—Kirk McKay
Educational Objectives
After completing this continuing education program, participants will be able to:
  1. Discuss the clinical indications of the new drugs approved by the FDA in 2013.
  2. Explain the various mechanisms of action of the drugs discussed within this program.
  3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
  4. Identify the most common adverse reactions for the new drug approvals in 2013.
  5. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: February 12, 2014
Expiration date: February 12, 2016
Estimated time to complete activity: 2 hours
Fee: Free

Click here to view this activity.

Description: Description: Description: Pharmacy Times/Ascend Media Office of Continuing Professional EducationPharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-14-003-H04-P. The activity is available for CE credit through February 12, 2016.

Latest Articles
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Latest Issues